Digital Health News | pharmaphorum

News

Lundbeck names AI head in quest to become 'bionic' company

Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.

News

Novo partners with Hims & Hers again, ending GLP-1 spat

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

Man on his smartphone while sitting on sifa

Daiichi teams up with GAIA for cholesterol DTx in Europe

Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

Lundbeck names AI head in quest to become 'bionic' company

Novo partners with Hims & Hers again, ending GLP-1 spat

Daiichi teams up with GAIA for cholesterol DTx in Europe

Alnylam bets on Tenaya RNAi tech, and other licensing news

Welsh firm Antiverse raises funds for AI antibody platform

FDA ramps up its pushback against compounded GLP-1s

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks